

AstraZeneca

Jo Mills, Director of Planning and New Communities
South Cambridgeshire District Council
South Cambridgeshire Hall
Cambourne Business Park
Cambourne
Cambridge
CB23 6EA

12 May 2014



Dear Jo,

Cambridge and South Cambridgeshire Local Plan Reviews Cambridge South Project

AstraZeneca are a global, innovation-driven, biopharmaceutical company specialising in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare. Last year we announced that we will establish a new global R&D centre in Cambridge, UK, by 2016. This includes an investment of around £330 million and underscores Cambridge's global importance as a location for biopharmaceutical research and development.

Cambridge offers invaluable access to world-leading scientific expertise and provides excellent opportunities for collaboration with renowned academic research institutions, pre-eminent hospitals and cutting-edge biotech companies. We hope our increased presence in Cambridge will help build the strength of the Cambridge bio-pharma community as a whole, enhancing the knowledge base and contributing to collective problem solving essential to the delivery of much-needed medical advances.

We have already started the transition Cambridge in advance of the main move in 2016, through the acquisition of temporary office accommodation in Melbourn and temporary laboratory space on the Cambridge Science Park. Through that exercise we have become aware of the lack of available commercial space within the Greater Cambridge area, particularly within walking or short cycling distance from our new facility at the biomedical campus.

The Cambridge South Project proposes the creation of a science park in close proximity to the biomedical campus. AstraZeneca supports the creation of this additional laboratory and commercial space, adjacent to the established concentration of medical and research institutes on the south side of Cambridge which first attracted us to the area. We believe it will provide a suitable environment to further enhance the biotechnology base which will drive the development of the innovative new technologies and drugs of the future.

Yours Faithfully,

Morris
Vice President & UK Footprint Lead, AstraZeneca



Councillor Robert Turner
Planning Portfolio Holder
South Cambridgeshire District Council
South Cambridgeshire Hall
Cambourne Business Park
Cambourne
Cambridge
CB23 6EA

6 October 2015

Dear Councillor Turner

Need for further research/commercial R&D and residential accommodation close to Cambridge Biomedical Campus

The University of Cambridge has extensive activity on the Cambridge Biomedical Campus, working alongside healthcare delivery by the hospital and research of third-party organisations that include Cancer Research UK and AZ. In due course we will be entering into further research activity alongside the new Papworth Hospital. We consider it a very important area for Life Sciences research.

The take up of land at the Biomedical Campus has been far faster than anyone had anticipated, and we feel it necessary to encourage Local Authorities to plan for development in this area as a consequence. In 2009, planning permission was granted for up to 215,000 sq m of floor space, approximately a third of which is intended for Addenbrooke's own development. Since that time, development projects by the MRC, Papworth Hospital, AZ and ourselves have been committed to on the other two thirds. As a result, the phase 2 land, originally anticipated for development post 2016, already has some reservations over it. In land take terms, Phase 1 provided a gross acreage of 70 acres, of which all but the land reserved for Addenbrooke's has been spoken for within a six year period. Phase 2 land will total approximately 15 acres and one can see that within just a few years from now that will have gone too.

With so little land now available at the Campus and with the Councils undertaking further work on the Local Plans, we feel we must write to draw your attention to the pending situation of need exceeding supply to 2031. Without action to address this now, the research and commercial R&D activity will be constrained in the early years of the plan period, unless further significant allocations can be made.

74 Trumpington Street
Cambridge CB2 1RW

Tel: 01223 337806
Fax: 01223 766486

Email: Roger.Taylor@admin.cam.ac.uk
www.admin.cam.ac.uk/offices/em

In addition to the needs for growing research and commercial R&D activity, I would also point out that the University is growing its student activity on the south side of Cambridge as the Schools of Clinical Medicine and the Biological Sciences continue to play a central role at the Biomedical Campus. Additional residential accommodation on this side of the city would help to support growth in numbers of researchers and teaching staff as well as to create a highly sustainable, joined-up community where people can live close to where they work, study and undertake research (often at all hours of the day and night).

We very much hope that the release of land within easy walking and cycling distance of CBC to meet this demand will be considered with some urgency by both councils - to help ensure the ongoing competitiveness of this University into the future.

If there is any matter you wish to discuss in further detail I would, of course, be happy to meet.

Yours sincerely

Roger Taylor

Copy to:

Ms Jean Hunter, Chief Executive, South Cambridgeshire District Council
Councillor Ray Manning, Council Leader, South Cambridgeshire District Council
Councillor Kevin Blencowe, Portfolio Holder for Planning Policy and Transport,
Cambridge City Council

Mr James Buxton
Pigeon Investment Management Ltd
Linden Square
146 Kings Road
Bury St Edmunds
Suffolk
IP33 3DJ

8 November 2016

Dear James,


Cambridge South Development

Thank you for your update regarding the Cambridge South Development.

I am writing to confirm GCGP's support for finding a solution to unlock additional land close to the Bio-Medical Campus. The Bio-Medical Campus has rapidly gained a global reputation for excellence in the Life Science sector. This has meant it has become a very sought after location, as denoted by Astra Zeneca's investment. This sector is also a key growth area for the UK, particularly in light of our departure from Europe.

The issue of finding additional land to support this global cluster is paramount. If supported by infrastructure improvements, we can see a highly successful development that supports UK plc but perhaps more importantly providing additional space to ensure Cambridge remains one of the very few global centres of excellence for the Life Science sector.

Yours sincerely,



Mark Reeve
Chairman
Greater Cambridge Greater Peterborough LEP
www.gcgp.co.uk